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Abstract
Metabolomic studies of body fluids show that immune-mediated inflammatory diseases such as 
rheumatoid arthritis (RA) are associated with metabolic disruption. This is likely to reflect the 
increased bioenergetic and biosynthetic demands of sustained inflammation and changes to 
nutrient and oxygen availability in damaged tissue. The synovial membrane lining layer is the 
principle site of inflammation in RA. Here the resident cells are the fibroblast-like synoviocytes 
(FLS) and the synovial tissue macrophages (STM), which are transformed toward overproduction 
of enzymes which degrade cartilage and bone, and cytokines which promote immune cell 
infiltration. Recent studies have shown metabolic changes in both FLS and macrophages from RA 
patients and these may be therapeutically targetable. However, as the origins and subset specific 
functions of synoviocytes are poorly understood and the signaling modules which control 
metabolic deviation in RA synovial cells are yet to be explored, significant additional research is 
needed to translate these findings toward clinical application. Furthermore, in many inflamed 
tissues, different cell types can forge metabolic collaborations through solute carriers (SLC) in 
their membranes, to meet a high demand for energy or biomolecules. Such relationships are likely 
to exist in the synovium and are yet to be explored. Finally, it is not yet known whether metabolic 
change is a consequence of disease or if primary changes to cellular metabolism might underlie or 
contribute to early stage disease pathogenesis. This article collates what is known about 
metabolism in synovial tissue cells and highlights future research directions in this area.
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Introduction
Rheumatoid arthritis (RA) is a systemic chronic inflammatory disease which principally 
manifests in the articular joints. Recent research has yielded biological therapies and small 
molecules to target signaling pathways and pathogenic components involved in 
inflammation and immunity, but in spite of these reasonably successful treatments, very few 
RA patients are able to achieve and stay in a state of drug-free remission. Innovative 
strategies are needed to obtain new insights into mechanisms which underlie disease 
pathogenesis and to identify potential new treatments.
In fields such as oncology, the concept of undermining or reprogramming metabolism to 
improve patient outcomes is established and we and others believe the potential is great to 
adopt similar strategies in immune-mediated inflammatory diseases (IMID) (1, 2). For three 
decades researchers have hypothesized an intermediate role for metabolic alterations and 
local hypoxia in RA pathology (3, 4). Indeed, RA and related IMID are associated with 
systemically measurable metabolic disruption. This is likely to reflect the increased 
bioenergetic and biosynthetic demand placed on immune and stromal cells in a chronically 
activated state. We now have the tools to better understand and translate past observations 
and to explore our hypothesis that metabolic deviation in synovial cells has a role in early 
pathogenesis rather than being a consequence of tissue damage. Qualitative changes to 
cellular metabolism are indeed essential to support physiological and pathological responses 
seen in the RA synovium and we describe these changes below. RA-associated 
characteristics include proliferation, migration and invasion that are hallmarks of activated 
fibroblast-like synoviocyte (FLS) behavior, and also proinflammatory mediator production 
characteristic of activated synovial tissue macrophages (STM) (5–7). The phenotypic 
transformation of FLS from a quiescent cell to an aggressive, metabolically active cell, the 
activation of STM, and the increasingly hypoxic and nutrient deprived microenvironment 
which develops in the RA joint are characteristics which closely resemble those seen in solid 
tumors.
Immunometabolism research has recently expanded in the footsteps of the more advanced 
cancer metabolism literature and this has led to the identification of potential new drug 
targets for immune-mediated pathologies(1, 8). Limitation of metabolic substrate 
availability, modulation of signaling pathways which control metabolism and targeting of 
channels through which metabolic intermediates are shared are exciting new strategies for 
treatment. Since there is now a widespread acceptance that the future of RA treatment may 
lie in targeting the synovial tissue and in particular the stromal microenvironment, it is 
logical to apply these new therapies here (9, 10). In this review, we describe our current 
knowledge of synovial metabolism and the therapeutic opportunities this field might present. 
We focus upon the FLS and STM which together form a destructive frontier and whose 
aberrant behavior is underpinned by pathological metabolic changes.
A systemic metabolic phenotype in RA
Metabolic perturbations have long been associated with RA and the hallmark ‘calor’ (heat) 
observed in the rheumatoid joint is widely considered a consequence of metabolic activity. 
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Daily resting whole body energy expenditure is 8% higher in RA than in healthy individuals 
suggesting these metabolic changes are significant and systemic (11). RA patients have an 
increased susceptibility to cardiovascular comorbidity and metabolic syndrome during the 
progression of their disease, associated with disruption of lipid and glucose metabolism (12). 
Furthermore, the catabolic condition ‘cachexia’ occurs in RA, with muscle atrophy and gain 
in fat associated with systemically elevated pro-inflammatory cytokines such as TNFα, 
IL-1β, LIF, IFNγ and IL-6 (13). Untargeted metabolomic studies of body fluids are helping 
to characterize the systemic observations alluded to above. These involve analysis of small 
molecules (<3kDa) usually using one-dimensional nuclear magnetic resonance (1D NMR) 
spectroscopy or mass spectrometry coupled to gas or liquid phase separation techniques, 
technologies which we have recently compared and evaluated (14). This approach has 
highlighted urinary metabolite signatures which can identify the six most prevalent immune-
mediated inflammatory diseases (15), and a serum metabolite signature which correlates 
with C-reactive protein (CRP) level and associates metabolism with underlying 
inflammatory mechanisms (16). Serum (17) and synovial fluid (SF) (18, 19) metabolomic 
profiles have also demonstrated the potential to distinguish RA from psoriatic arthritis and 
other diseases (14). Furthermore, our data and that of others show that patient responses to 
biological therapies including etanercept and rituximab can be predicted from urine, serum 
and plasma metabolic profiles, highlighting the power of metabolomics in stratifying 
patients and directing RA treatment (20–22).
Since immune and stromal cells within the inflamed joints are known to produce 
inflammatory cytokines it is likely that they are contributing to the global metabolic 
phenotype in RA. However, the metabolic profiles of individual cell types involved in 
chronicity or resolution of inflammation have sparsely been elucidated. This will be 
important to link diseases associated metabolites to pathogenic processes and to gain a full 
understanding of RA pathogenesis.
The rheumatoid synovium
Though RA is a systemic disease, the major manifestation is joint pain and loss of function. 
The normal diarthrodial joint is lined with a thin, soft-tissue membrane, the synovium, 
which comprises a sublining and a thin intimal lining layer, and which produces and 
encapsulates a lubricating hyaluronic acid-rich fluid (23). Resident to the tissue are two 
heterogeneous and inadequately characterized cell types a) the STM; a mixed population of 
prenatally seeded cells and those which have differentiated from circulating monocytes (24, 
25), and b) the FLS, mesenchymal-derived cells, which compared with fibroblasts in other 
anatomical locations, are characterized by the expression of UDP-glucose 6-dehydrogenase, 
an enzyme required for the synthesis of hyaluronic acid, and of complement decay-
accelerating factor (also known as CD55) (26). Collaborative networks such as the National 
Institutes for Health Accelerating Medicines Partnership are facilitating the effective 
digestion of tissue to obtain pure populations of FLS and STM. This combined with a 
growing profile of soluble and surface markers and revolutions in fate mapping and single 
cell analysis techniques is improving our ability to study and understand the functions of 
these important cells (27, 28).
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The hallmark of RA is macroscopically visible change to the synovial lining layer which 
becomes inflamed, hyperplastic and invasive of local cartilage and bone (29). This is driven 
by a complex interaction between chronically activated and epigenetically transformed 
synoviocytes and infiltrating cells of the innate and adaptive immune system (5, 30). Both 
FLS and STM contribute to synovial inflammation by production of mediators which recruit 
and activate immune cells. Importantly, these cells also drive each other’s activation and 
survival by paracrine production of cytokines such as TNFα and GM-CSF (30). However, it 
is the FLS in the intimal lining which form the aggressive pannus and are the major effectors 
of tissue damage through production of extracellular matrix degrading enzymes such as 
matrix metalloproteinases and cathepsins (30).
Though the joint exists at an oxygen tension as low as 8% even in health, the 
microenvironment in RA is characterized by severe hypoxia at oxygen tensions which fall to 
below 1% (31). Nutrient availability is also low as immune cells and activated synoviocytes 
consume available resources at a rate which exceeds their delivery. Synovial angiogenesis, 
which is mediated by factors released by both FLS and STM and enhances the ingress of 
leukocytes into the synovial tissue, is insufficient, and the aggressive front formed by the 
hyperplastic synovial lining increases the distance between blood vessels and synoviocytes 
(32, 33). RA FLS are transformed from a quiescent state to an aggressive, invasive 
phenotype and they persist despite enrichment of apoptosis-inducing factors such as oxygen 
radicals, nitric oxide and cytokines supplied by activated STM. As such the synovium bears 
resemblance to tumor tissue and cells are likely to be subject to similarly elevated 
bioenergetic and biosynthetic demands to those seen in cancer. This comparison is 
summarized in Figure 1.
It is likely that adaptation of mitochondria and cytoplasmic metabolic pathways is needed to 
meet the requirements of chronic inflammation in RA. Indeed, of the few studies which 
profile the metabolome of FLS, profound metabolic differences were identified in end stage 
RA when compared with OA and many of these are described below (34, 35). Our 
unpublished data shows a correlation between systemic inflammation (measured as CRP) 
and the metabolic profile of FLS from very early RA. However, studies comparing to 
healthy FLS or assessing changes during the transformation in early disease are lacking. 
Consequently, we are currently unable to determine if metabolic adaptation of fibroblasts is 
a normal response to chronic inflammation, or if primary changes to cellular metabolism 
might themselves underlie or contribute to the disease pathogenesis. Studies of STM are also 
few and most of what is known about RA macrophage metabolism is from animal models or 
study of cells differentiated in vitro from SF or peripheral blood monocytes (36). Since 
macrophages in healthy synovium are thought to be largely yolk sac-derived and cues 
leading to monocyte differentiation in tissue are poorly defined, there is a pressing need for 
better characterization of synovial macrophage subsets and their metabolism (37).
The dynamic metabolic response in health
The function of the metabolic machinery within a cell is to provide the energy and 
biomolecules necessary to perform resting and activated functions, while managing the 
production of potentially damaging byproducts such as lactate and reactive oxygen species 
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(ROS). Recent studies of immune cells have identified important roles for metabolism in 
supporting and even directing cell differentiation and fate. These studies have characterized 
the extent of metabolic plasticity required for cellular responses to stimulation (8). There are 
6 main pathways which are involved in these functions (summarized in Figure 2). Of these, 
oxidative phosphorylation (comprising the tricarboxylic acid TCA cycle and the 
mitochondrial electron transport chain) and fatty acid oxidation are oxygen dependent and 
take place in the mitochondria, while utilizing substrates taken up from the cytoplasm. 
Glycolysis, the pentose phosphate pathway (PPP), amino acid metabolism and fatty acid 
synthesis are oxygen independent and largely take place in the cytoplasm. However, fatty 
acid and amino acid intermediates are also shared with mitochondrial processes and use of 
the PPP to maintain redox balance does require oxygen (8).
Normal physiological metabolism and metabolic responses to inflammatory events are 
poorly studied in tissue resident populations such as fibroblasts and embryonically seeded 
macrophages(25). This is largely due to the practicalities of disentwining cells from the 
extracellular matrix, a challenge which researchers are making great efforts to address (38). 
Indeed there has been limited progress since the stromal metabolism field was thoroughly 
reviewed in 2014 (39). One study defines what is known about resting, healthy fibroblast 
metabolism, showing that fore-skin derived cells are predominantly glycolytic and 
dependent upon the PPP even in quiescence (40). This supports the anabolic processes 
associated with extracellular matrix production and is likely to also apply to FLS which 
maintain SF and produce it in excess in RA.
Reversible regulation in the balance of cytoplasmic and mitochondrial metabolism is crucial 
for all cells to respond and adapt to changing microenvironments. Metabolic change is 
orchestrated by signaling pathways responding to nutrient, energy and oxygen levels as well 
as growth factor, pattern recognition, and cytokine receptors. The pathways involved have 
been reviewed elsewhere (41, 42) and are summarized in figure 2. These include the master 
regulators mechanistic target of rapamycin (mTOR) and 5′ adenosine monophosphate 
activated protein kinase (AMPK) pathways which work in opposition to one another. The 
mTOR network is a nutrient sensing system. mTORC1 or mTORC2 complex formation 
downstream of PI3K or MAPK pathways induces activation of AKT and transcription 
factors HIF1α and MYC, which in turn activate glycolytic pathway genes upregulating 
aerobic glycolysis. Sterol regulatory element binding proteins (SREBP) and peroxisome 
proliferator-activated receptor gamma (PPARγ) acting downstream of mTORC1 also 
activate genes which upregulate fatty acid synthesis. Other pathways have also been shown 
to activate glycolysis in a HIF1α independent manner, including the NF-κB pathway 
involving ubiquitous phosphofructokinase 2 (uPFK2). AMPK is an energy sensing system 
often considered a metabolic checkpoint as it can inhibit glycolysis, control cell proliferation 
and promote mitochondrial biogenesis when activated under energetic stress (43, 44). 
Downstream nuclear respiratory factor-1 (NRF-1), NRF-2 and PPARγ coactivator-1α 
(PGC-1α), as well as SIRT1 or STAT6 activated PGC-1β, induce mitochondrial biogenesis 
and fusion (discussed below), induce protective antioxidant enzymes, and promote oxidative 
metabolism. The mTOR pathway has also been shown to be important in polarization of 
macrophages to pro-inflammatory (M1) or pro-resolving (M2) phenotypes and in activation 
of both macrophage subtypes, and this has been thoroughly reviewed (45). AMPK activation 
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in macrophages is associated with suppression of IL-6 production, anti-inflammatory M2 
macrophage differentiation from SF monocytes and suppressed inflammation in K/BxN 
serum induced arthritis (46, 47). The signaling pathways which instruct stromal cell 
behavior are less well defined. mTOR activation has been linked to invasive properties in 
arthritic rat FLS (48). Furthermore, mice deficient in NRF2 which acts downstream of 
AMPK, show more severe cartilage injuries and more oxidative damage in a murine model 
of arthritis (49). However, no link between metabolism and cell signaling has yet been made 
in human FLS or STM and it is unknown whether signaling pathways controlling metabolic 
phenotype are dysregulated in RA.
Mitochondrial responses in the RA synovium
Under normoxic conditions mitochondrial oxidative phosphorylation is the most efficient 
source of ATP (50). In addition, mitochondria integrate various metabolic pathways and 
through this process produce intermediates needed for the synthesis of lipids, steroid 
hormones, and heme. Other more specialized mitochondrial functions include maintenance 
of Ca2+ homeostasis, regulation of apoptosis, and production of the physiological levels of 
ROS which act as signaling molecules (50). Importantly, mitochondria have mechanisms to 
respond spatially and temporally to heterogeneous nutrient and oxygen concentrations, 
increased ATP demands and increased stress signals including oxidative stress, for continued 
support of cellular functions and survival. These mechanisms include the overexpression of 
antioxidant enzymes and remodeling of respiratory complex subunits, changes in substrate 
choice (utilizing glutamine, pyruvate, fatty acids and ketone bodies) or switching toward 
increased glycolysis when energetic demand outpaces oxygen delivery (50).
Changes in mitochondrial biogenesis, mitochondrial-selective autophagy (mitophagy) and in 
the equilibrium between mitochondrial fusion and fission are also critical to maintain normal 
mitochondrial and cellular function (Table 1 and Figure 3). Mitochondrial biogenesis is 
induced through the signaling pathways described above, not only in association with cell 
division but also in response to oxidative stimuli and increased energy requirements. The 
flux between fusion and fission of mitochondria in response to stress is also crucial to 
maintaining the metabolic capacity of the mitochondria as well as protecting genetic 
stability. Mitophagy plays a pivotal role in the maintenance of mitochondrial homeostasis, 
regulating the size and quality of the mitochondrial population. In addition, mitophagy 
eliminates damaged mitochondria under diverse stress conditions, which is critical as 
mitochondrial DNA (mtDNA) is a damage-associated molecular pattern (DAMP) that 
contributes to systemic inflammatory responses (51). Excess or inadequacy in mitochondrial 
dynamics, biogenesis and mitophagy are deleterious in mice and are associated with aging 
and multiple serious human diseases, highlighting their importance in cell phenotype and 
function (51, 52). Furthermore, mitochondrial surveillance and quality control mechanisms 
including mitochondrial biogenesis and mitophagy decline with age causing progressive 
deterioration of mitochondrial function. This may have a role in diseases such as RA and 
suggests that targeting mitochondrial processes could be beneficial to restore cell function 
(53).
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Surprisingly little is known about mitochondrial dynamics and function in RA synoviocytes 
and there is a particular absence of observations in STM. However, a growing literature 
describes mitochondrial metabolism downstream of glycolytic glucose consumption and its 
role in differentiation and activation of pro-inflammatory and pro-resolving monocyte-
derived macrophages subtypes. These model systems might inform research in the 
synovium. For example, stimulation of macrophages with lipopolysaccharide (LPS) and 
interferon gamma (IFNγ) (so-called M1-polarising conditions) produces proinflammatory 
cells which may resemble those which populate the RA synovium. This leads to inhibition 
of the TCA cycle and the mitochondrial oxidative phosphorylation pathway to which it is 
coupled and results in upregulation of glucose transporter 1 (Glut1) to facilitate efficient 
uptake of glucose. Glucose is consumed through upregulation of aerobic glycolysis and 
gives rise to production of copious lactate which must be extruded from the cell to prevent 
lactic acidosis (54). Production of reactive oxygen is increased, partly as a consequence of 
reversed electron transport by mitochondria and certain intermediates of the TCA cycle 
accumulate, notably succinate. This promotes expression of the pro-inflammatory cytokine 
IL-1β by inhibiting prolyl hydroxylases and activating the transcription factor HIF-1a. 
Succinate has also been linked to changes in methylation of DNA and associated histone 
proteins to alter gene expression (55). Furthermore, isocitrate is diverted from the Krebs 
cycle and metabolised to itaconic acid, another more recently identified TCA cycle inhibitor 
(56). RA synovial macrophages express HIF-1a, consistent with a switch to glycolytic 
metabolism but efforts are required to characterize mitochondrial metabolism and dynamics 
in resident and infiltrating STM (57).
Several studies have observed mitochondria in late stage RA FLS. Baseline reductions in 
respiration and membrane potential (58) and changes to mitochondrial morphology (59) 
have been shown when compared with OA. Further changes suggestive of mitochondrial 
dysfunction such as perinuclear clustering of mitochondria, abnormally dark cristae, and 
autophagosome formation have been associated with lower basal mitochondrial membrane 
potential, as well as lower basal, maximum and ATP-linked mitochondrial respiratory rates 
(58). In a complementary study also in comparison with OA, we recently showed RA FLS 
had a higher baseline glycolytic rate to respiratory rate ratio, implying a shift toward reliance 
on glycolysis to meet the energy demand of the cells (60). Changes in mitochondrial 
metabolism can be induced in FLS by cytokines and growth factors including IL-17, TNF 
and PDGF which are associated with RA and related inflammatory conditions (58, 61). The 
reported consequences, though incompletely understood, include reduced ATP production 
by oxidative phosphorylation, production of excessive reactive oxygen and nitrogen species, 
dysregulation of Ca2+, opening of the permeability transition pore and initiation of cell death 
in vitro. Significant increases in mtDNA mutation frequency have been demonstrated in 
inflamed synovial tissue and were positively correlated with macroscopic synovitis, 
vascularity and SF levels of TNF and IFNγ (62). A further study showed that exposure of 
RA synovial tissue to 1% oxygen in vivo induced mtDNA mutations suggesting that the 
inflamed and hypoxic joint microenvironment may be eliciting the mitochondrial changes 
observed in RA FLS and likely to be occurring in STM (31). Hypoxia also altered the 
bioenergetics of cultured FLS by promoting a switch to glycolysis while attenuating 
mitochondrial respiration and ATP synthesis. This supported abnormal angiogenesis, cellular 
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invasion and pannus formation (59). Further in vitro studies have indicated higher mtDNA 
mutations and ROS levels in RA compared to OA FLS (63), correlating with elevated matrix 
metalloproteinase (MMP) expression and an invasive phenotype in RA (61, 64).
The above findings suggest that there are mitochondrial changes in late stage RA FLS which 
are maintained in in vitro culture, yet we lack understanding of which changes are a normal 
response to meet metabolic demands of inflammation, which might play a role in driving the 
pathology of chronic disease and which are the result of damage and an increasingly 
hypoxic environment. In fact, resistance to induction of programmed cell death (apoptosis) 
by apoptotic signals abundant in the inflamed joint, is a prominent characteristic of the RA 
synovium (65) and sustains the synovial hyperplasia that characterizes the rheumatoid 
pannus. This would suggest that mitochondrial responses induced by hypoxia and 
inflammation in synoviocytes are able to repurpose the mitochondrion as a biosynthetic hub 
similar to that of tumor cells (66) and with conserved mechanisms for limiting oxidative 
stress and supporting effector functions and proliferation (5). Finally, although we lack 
information regarding mitophagy in the synovium, it has been suggested that TNF 
significantly induces mitophagy and mitochondrial antigen presentation in mouse 
macrophages with implications for RA (67). Several reports have shown altered autophagy 
in RA FLS, which could also contribute to synovial hyperplasia. RA FLS show an increase 
of genes involved in autophagy such as beclin-1 and LC3, which inversely correlate with 
their apoptosis rate (68, 69). In addition, RA FLS under endoplasmic reticulum stress may 
increase autophagy while becoming resistant to apoptotic death (70). Further studies are 
needed to understand the tangled relationship between metabolism, apoptosis and autophagy 
in synoviocytes and to identify whether restoring normal metabolism and mitochondrial 
function might have therapeutic potential in RA.
Glucose metabolism in the RA synovium
Glucose and other metabolites such as glutamine, fatty acids, and ketone bodies can be 
metabolized through the mitochondrial tricarboxylic acid (TCA) cycle in metabolically 
active tissues, but a shift away from oxidative phosphorylation towards aerobic glycolysis 
often occurs in response to cellular activation and in inflamed tissues (71). This supports 
various biosynthetic pathways and, consequently, the metabolic requirements for 
proliferation and cytokine production. Accelerated glucose metabolism is a hallmark of 
proliferative and activated cells (72) and can be observed with clinical imaging. Several 
studies have used fluoro-2-deoxyglucose (FDG) which is taken up by glycolytic cells to 
form FDG-phosphate, and can be shown by positron emission tomography (PET) to 
accumulate in swollen joints (73). Indeed, glycolytic inhibition by BrPa administered in a 
serum transfer animal model significantly decreased arthritis severity, highlighting the 
importance of glucose metabolism in fueling pathological processes and making it a 
promising target for therapeutic intervention in RA (60). However, as discussed in a recent 
review by Weyand et al comparing macrophages and T cells, cells can coexist in the same 
microenvironment and utilize metabolites differently(74). This highlights the need to dissect 
glucose utilization in different synoviocytes since any successful treatment will necessarily 
be cell type specific.
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Metabolic profiling of synovial tissue has revealed that FLS consistently show altered basal 
glucose metabolism in RA (34, 35, 75), and we and others have found that stimuli such as 
PDGF or TNF increase in vitro glucose metabolism by both glycolysis and mitochondrial 
respiration (60). Furthermore, the glucose channel Glut1 is upregulated in response to 
hypoxia and cytokines and correlates with phenotypic perturbations in RA FLS (59, 60). 
Glucose deprivation or glycolytic inhibitors such as 2-deoxy-D-glucose (2-DG), 
bromopyruvate (BrPa) (60) and 3-(3-Pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (59) have 
been shown to impair cytokine secretion, proliferation, migration and invasion in RA FLS. 
Although, glucose metabolism is enhanced in activated macrophages, no data in STM is 
available yet.
Diversion of glucose metabolism away from glycolysis and toward the PPP is important to 
support biosynthetic role of some cells. A role for this pathway in RA was highlighted by 
work on T cells which showed impaired glycolytic flux due to elevated pentose-shunt 
activity and up-regulation of phosphofructokinase (76). In light of RA synoviocyte 
mitochondrial responses and elevated ROS production described above, increased flux of 
glucose through the PPP might also be expected in these cells to produce cytoplasmic 
NADPH, and drive the reducing power of ROS detoxifying enzyme systems in both the 
cytoplasm and the mitochondrial compartments. Indeed, a global increase of glucose 
metabolism (both the PPP and glycolysis) was observed in total synoviocytes (4), and recent 
metabolite profiling of FLS (77) showed both metabolites from glycolysis and PPP were 
significantly increased in RA and compared to OA, together with other metabolites that 
belonged to the amine, fatty acid, phosphate, and organic acid classes. Although this hints 
toward the importance of the PPP, its role and the importance of NADPH production and 
other antioxidant mechanisms such as the glutathione oxidation pathway have not yet been 
dissected in FLS and resident STM populations and such research might yield new 
opportunities for therapeutic intervention in RA.
Secondary roles have emerged for glucose metabolites, metabolic enzymes and TCA cycle 
intermediates outside of metabolism. For instance, succinate stabilizes the transcription 
factor HIF-1α in activated macrophages and also rat synovial fibroblasts promoting 
glycolysis (55, 78). Succinate and other metabolites including α-ketoglutarate, fumarate and 
acetyl-CoA might be expected to accumulate in macrophages and FLS under hypoxic 
conditions and are involved in eliciting important epigenetic changes, with unexplored 
potential for driving chronic inflammation (55, 78). Also, essential glycolytic enzymes have 
been reported to translocate to the nucleus or mitochondria where they function 
independently of their canonical metabolic roles in regulation of cytokines and anti-
apoptotic responses (79, 80). For example, PKM2 also stabilizes HIF-1α promoting 
inflammatory M1 macrophage differentiation. Use of a small molecule modulator of PKM2 
to prevent nuclear translocation has potential for driving a shift toward an M2 phenotype and 
restoration of tolerance in diseases such as RA. The hexokinase (HK) enzymes are also 
important regulators of metabolism. HK1 is known to drive cleavage and activation of pro-
IL-1β in macrophages via the NLPR3 inflammasome and the downstream activation of 
caspase 1 (81), though this has not been studied in STM. HK2 also binds to the 
mitochondrial membrane via its interaction with the outer membrane porin protein (also 
termed the voltage-dependent anion channel (VDAC)) and this interaction inhibits the 
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release of intermembrane pro-apoptotic proteins, thereby protecting cells from apoptosis. 
Importantly, the expression of HK2 is increased in RA FLS compared to OA FLS, and might 
provide an important link between metabolism and apoptosis resistance in the RA synovium 
(60).
Lipid metabolism in the RA synovium
Though a complex and incomplete picture, lipids are known to be important in fueling 
adaptive immunity and in resolution of inflammation (8, 82). A few studies have described 
lipid changes in RA FLS, although this has not been studied in STM. Metabolomic profiling 
has shown perturbation of lipid metabolism in RA FLS versus OA cells (34), and recent 
studies have identified important roles for molecules which interact with lipids such as 
choline, an important component of membrane phospholipids which may be limiting in 
proliferating cells such as RA FLS. Choline C-11 PET scanning, which is already in clinical 
use to identify prostate cancer metastasis, showed increased uptake in inflammatory arthritis 
joints (83) and choline is present at elevated levels in RA FLS and synovium (34, 75). Of 
interest, choline like transporter (CTL)1 (high-affinity) and CTL2 (low-affinity) are also 
highly expressed in RA FLS and the functional inhibition of choline transporters promoted 
apoptotic FLS cell death (84). We have also shown possible therapeutic benefit in targeting 
choline kinase (ChoKα), the enzyme that catalyzes the first step in the cytidine diphosphate-
choline pathway and which is essential for phosphatidylcholine (PC) biosynthesis. Its 
inhibition suppressing migration and enhancing apoptosis in cultured RA FLS, and 
significantly decreasing experimental arthritis in pre-treatment protocols as well as in 
established disease (35). Related to PC metabolism, phospholipase D (PLD) enzymes 
specifically cleave PC producing phosphatidic acid (PA) and choline. Agonist-induced PLD 
activation results in PA synthesis thought to be involved in a variety of rapid cellular 
responses such as cytokine secretion (85). In RA FLS and RA synovial biopsy explants, 
PLD isoform-specific inhibitors significantly reduced constitutive secretion of IL-6 and 
IL-8, further highlighting the importance of phospholipid metabolism in inflammation (86). 
Another study showed that activated inflammatory arthritis FLS from humans and animal 
models express significant quantities of autotaxin, which catalyzes the conversion of 
lysophosphatidylcholines (LPC) to lysophosphatidic acid (LPA). Notably, high levels of 
LPC and low PC/LPC ratios in plasma were shown to represent a reliable measure of 
inflammation (87). TNF induced autotaxin expression from FLS and LPA, in turn, induced 
an activated FLS phenotype in synergy with TNF (88, 89). Conditional genetic ablation of 
autoxin in mesenchymal cells, including FLS, resulted in disease attenuation in animal 
models of arthritis (90).
Metabolic coupling of cells in the RA synovium
The problem with many of the studies described above is that they tend to treat FLS and 
STM as if they exist in isolation. But metabolism is not a private function, and metabolites 
produced by one cell can have profound effects on the biology of another. As described 
above, metabolites such as succinate, citrate and isocitrate accumulate in inflammatory 
macrophages and control metabolism in a feedback loop. It is possible that such metabolites 
derived from STM might have a role in influencing metabolism and function of proximal 
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FLS, but this is yet to be investigated. Indeed, metabolite exchange between stromal and 
parenchymal cells is an essential function common to numerous metabolically active tissues 
including muscle, nerve, kidney, liver and testicle. SLC including the monocarboxylate 
transporters (MCT) are employed as a means of physiological metabolic coupling between 
different cell types, as extensively reviewed (91). Here macrophage-like cells commonly 
provide high-energy metabolic intermediates such as lactate and pyruvate to bioenergetically 
demanding partner cells where they can anaplerotically fuel the TCA cycle. A similar 
mechanism has been identified in epithelial cancers where both Warburg and so called 
‘Reverse-Warburg’ metabolisms have been demonstrated and highlighted as therapeutic 
targets (92). The Warburg effect describes upregulation of aerobic glycolysis in the tumor 
cell itself and in the presence of ample oxygen. The ‘Reverse-Warburg effect’ describes a 
situation in which cancer-associated fibroblasts (CAF) provide lactate, ketone bodies and 
amino acids passed through MCT to fuel tumor cell proliferative behavior (93), as well as 
local angiogenesis associated with metastasis (94). Due to commonalities in cell behavior 
and microenvironment, one could hypothesize that similar symbiotic relationships might 
exist in the synovium to fuel immune cell effector function and FLS pathogenic behavior 
(Figure 4). Fujii et al showed in 2015 that late stage RA FLS have elevated levels of MCT4 
compared to OA and that siRNA knockdown of MCT4 reduced arthritis severity in the 
murine collagen-induced arthritis model, linking their findings to apoptosis resistance and 
synovial acidification (95). Expulsion via MCT4 is likely to be a necessary mechanism to 
protect cells from damaging effects of lactate accumulation. However, whether the lactate 
can be taken up and utilized by other cells is unknown. It is very likely that the role of MCTs 
and the sharing of metabolites between cells will differ during the course of RA as a 
reflection of mitochondrial health and changes to the joint microenvironment. Consequently, 
it will be important to study metabolic coupling in normal tissue and in the acute phase of 
disease to determine whether such relationships exist and if so, exploit their therapeutic 
potential, as is showing promise in cancer (96).
Expanding knowledge of fibroblast metabolism
The study of metabolism in cultured synovial cells has been important in understanding RA 
biology. Such studies have illustrated a ‘metabolic memory’ which is epigenetically 
imprinted upon cells in an inflammatory microenvironment and is lasting in in vitro culture. 
Metabolomic analysis continues to be a useful strategy for providing a metabolic snapshot 
on the status of such cells and to hint toward pathways worthy of further study. Use of 
technologies such as the Seahorse analyzer to observe bioenergetic responses, small 
molecule metabolic inhibitors and animal models have also played a role in expanding our 
current understanding of the field. However, for capturing the dynamic processes that 
regulate cellular metabolism, stable isotope metabolic tracer analysis is a powerful technique 
not yet applied to synoviocytes (97). This technique provides a comprehensive biological 
overview, allowing simulation and reconstruction of metabolism, and can provide insight at 
the compartment level (e.g. mitochondria versus cytoplasm, depending upon the tracer) (98). 
The increased concentration of a metabolite can be associated to either the upregulation of 
the enzyme responsible for synthesis or the downregulation of the one consuming it and 
metabolic tracer analysis allows these processes to be deconvoluted where traditional 
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metabolomics is less informative (99, 100). Several heavy isotopes are available and include 
deuterium (2H), nitrogen (15N), oxygen (18O) but the most commonly used is carbon (13C). 
The most common isotopically labeled tracers are 13C-glucose and 13C-glutamine as these 
metabolites are main energy sources in many mammalian systems (101). Recent 
development of approaches to apply tandem mass spectrometry (MS/MS) to isotope tracing 
has offered the opportunity to determine positional labeling based on mass fragmentation 
(102).
As alluded to above, studying metabolic relationships of synoviocytes after treatment (103), 
and between FLS and STM within the RA synovium is an important future direction. Stable 
isotope analysis in concert with small molecule inhibitors will allow us to trace metabolite 
exchange between cells in culture. There is also a pressing need for conditional knock out 
animals to observe the importance of metabolite channels, transporters and enzymes in 
inflammatory diseases as an area of great therapeutic potential. Finally, better histological 
markers are improving our understanding of FLS subsets, resident and infiltrating STM and 
the tissue organization of these cells. Imaging mass spectrometry can provide a metabolomic 
snapshot on a per pixel basis and may reveal spatially distinct metabolic signatures and 
important metabolic heterogeneity within the synovial environment (104).
Metabolic pathways as therapeutic targets in rheumatoid arthritis
The metabolic rewiring of immune cells has been viewed as a promising source of novel 
drug targets (8, 14, 105) but resetting metabolism in tissues central to RA pathogenesis 
offers additional opportunities for disease modulation and restoration of homeostasis in RA. 
In fact, rheumatologists already use the antimetabolites methotrexate (MTX) and 
leflunomide for the treatment of patients with inflammatory arthritis. Both drugs inhibit the 
reproduction of rapidly dividing cells such as lymphocytes, but have also been shown to 
inhibit FLS functions (106, 107). Of interest, sulfasalazine, which was initially developed as 
an anti-inflammatory drug to treat rheumatoid arthritis, was subsequently found to inhibit 
XCT, a cystine–glutamate exchange transporter (108).
Targeted approaches to metabolic inhibition are required to inhibit aggressive behavior in 
pathological cell types and leave those which aid resolution intact. Potentiation or 
restoration of protective mechanisms such as mitochondrial fusion and biogenesis and 
mechanisms which promote resolution of inflammation may also be favorable. Indeed, small 
molecules such as Mdivi1 which potentiate mitochondrial fusion have already shown 
potential in animal models of sepsis and may have further reaching applications (109). In 
addition, metformin is used in clinical management of type II diabetes and has shown 
promise in mouse models of arthritis (110). Though its effects on FLS are unknown, it is 
thought to act upon immune cells both by inhibiting complex I of the mitochondrial electron 
transport chain and through effects on the signaling molecule AMPK. Other AMPK 
activators, which will control cell proliferation and promote mitochondrial biogenesis might 
be another approach (43, 44).
Inhibitors of the signaling molecule PI3K which regulates glycolysis upstream of mTOR are 
in early stage clinical trials for cancer and show potential in RA (111). Furthermore, 
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blockers of key glycolytic enzymes including phosphofructokinase-2/fructose-2,6-
bisphosphatase 3 (PFKFB3) are showing promise to work in synergy with other inhibitors 
that target the angiogenic factor VEGF (112). Inhibiting glycolytic intermediates including 
succinate or lactate production could be of interest if proven to fuel synovial cell activation. 
Use of a small molecule modulator of PKM2 to prevent nuclear translocation has also 
potential for driving a shift toward an M2 phenotype and restoration of tolerance in diseases 
such as RA. In FLS, HK2 release from the mitochondrial membrane could potentially 
trigger FLS apoptosis. However, a better understanding of the signaling pathways which 
dictate the metabolic phenotype of immune and stromal cells in RA is required to capitalize 
on this area.
Blockers of the MCT which are central to metabolic coupling have been used in as yet 
unpublished first-in-man trials for epithelial cancers, and the effects of their knockdown in 
experimental arthritis suggest they offer potential in RA (95). Other solute carrier 
transporters, including Glut1, aminoacids or choline are potential therapeutic targets yet to 
be explored in arthritis. Furthermore, better stratification of patients through prognostic 
metabolomic analysis (16) and techniques such as choline C-11 PET scanning (83) may 
improve treatment of non-responders to existing therapies. Overall, whether targeting 
metabolism truly presents an option to increase the drug armamentarium in rheumatic 
diseases remains to be determined.
Summary
Systemic metabolism, immunometabolism and stromal metabolism are altered in RA and a 
growing body of publications in this field offers novel biomarkers for patient stratification 
and avenues for treatment. However, we are far from an exhaustive understanding of the 
pathways which discern the normal or pathogenic phenotypes of cells resident to the 
synovium in order to capitalize on these therapeutic opportunities. It will be important to 
better understand mitochondrial metabolism and dynamics, which are sparsely studied in the 
synovium, with a view to harnessing fusion and biogenesis pathways to restore 
mitochondrial health and tip the balance away from aerobic glycolysis in RA. Future 
directions toward single cell transcriptomic analysis and use of cells sorted directly from 
synovial tissue promises to improve our understanding of FLS and STM biology and there is 
a need for metabolic profiling of these cells prior to dedifferentiation associated with cell 
culture. Growing evidence suggests that multiple fibroblast and macrophage subsets are 
present in the inflamed synovium and their characterization will aid in directing new 
treatment toward those with a pathogenic and not a protective phenotype. Furthermore, the 
metabolic interactions between FLS, STM and infiltrating immune cells are unexplored and 
lessons from cancer biology suggest this will provide further avenues for therapeutic 
intervention. There is a pressing need for techniques such as stable isotope-based metabolic 
tracer analysis to track these interactions. Finally, a strategic window of opportunity exists 
such that RA patients receiving disease modifying treatments within 3 months of symptom 
development show a much improved prognosis when compared to those treated after this 
time point (113). To date, all studies of FLS metabolism have been conducted in cells 
derived from the joints of late stage disease patients after arthroplasty and studies of 
macrophages have utilized cells differentiated from monocytes in vitro. As we begin to 
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understand that transient metabolic responses in acute inflammation may differ significantly 
from metabolic adaptation to damage in chronic inflammation, characterization of cells from 
uninflamed and earliest stages of human disease is needed to inform appropriate future 
therapeutic strategies with the ultimate goal of drug-free remission or cure for RA.
Acknowledgments
M.G. was supported by NIH 1K08AR064834, R03AR068094 and Rheumatology Research Foundation. This work 
was also supported by grants from the NIHR/Welcome Trust Clinical Research Facility, University Hospitals 
Birmingham NHS Foundation Trust and from Arthritis Research UK Grants: Targeting fibroblasts in the treatment 
of inflammatory arthritis (19791), Rheumatoid Arthritis Pathogenesis Centre of Excellence grant (20298) and 
Arthritis Research UK Experimental Arthritis Treatment Centre (20015).
References
1. Bettencourt IA, Powell JD. Targeting Metabolism as a Novel Therapeutic Approach to 
Autoimmunity, Inflammation, and Transplantation. J Immunol. 2017; 198(3):999–1005. [PubMed: 
28115589] 
2. Patel CH, Powell JD. Targeting T cell metabolism to regulate T cell activation, differentiation and 
function in disease. Curr Opin Immunol. 2017; 46:82–8. [PubMed: 28521236] 
3. Ahlqvist J. A hypothesis on the pathogenesis of rheumatoid and other non-specific synovitides. IV 
A. The possible intermediate role of local hypoxia and metabolic alterations. Med Hypotheses. 
1984; 13(3):257–302. [PubMed: 6371458] 
4. Henderson B, Bitensky L, Chayen J. Glycolytic activity in human synovial lining cells in 
rheumatoid arthritis. Ann Rheum Dis. 1979; 38(1):63–7. [PubMed: 434949] 
5. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and 
imprinted aggressors. Nat Rev Rheumatol. 2013; 9(1):24–33. [PubMed: 23147896] 
6. Bustamante MF, Garcia-Carbonell R, Whisenant KD, Guma M. Fibroblast-like synoviocyte 
metabolism in the pathogenesis of rheumatoid arthritis. Arthritis Res Ther. 2017; 19(1):110. 
[PubMed: 28569176] 
7. Naylor AJ, Filer A, Buckley CD. The role of stromal cells in the persistence of chronic 
inflammation. Clin Exp Immunol. 2013; 171(1):30–5. [PubMed: 23199320] 
8. O’Neill LAJ, Kishton RJ, Rathmell J. A guide to immunometabolism for immunologists. Nat Rev 
Immunol. 2016; 16(9):553–65. [PubMed: 27396447] 
9. Patel R, Filer A, Barone F, Buckley CD. Stroma: fertile soil for inflammation. Best practice & 
research Clinical rheumatology. 2014; 28(4):565–76. [PubMed: 25481550] 
10. Juarez M, Filer A, Buckley CD. Fibroblasts as therapeutic targets in rheumatoid arthritis and 
cancer. Swiss Med Wkly. 2012; 142:w13529. [PubMed: 22367980] 
11. Metsios GS, Stavropoulos-Kalinoglou A, Nevill AM, Douglas KM, Koutedakis Y, Kitas GD. 
Cigarette smoking significantly increases basal metabolic rate in patients with rheumatoid arthritis. 
Ann Rheum Dis. 2008; 67(1):70–3. [PubMed: 17502358] 
12. Cojocaru M, Cojocaru IM, Silosi I, Vrabie CD. Metabolic Syndrome in Rheumatoid Arthritis. 
Mædica. 2012; 7(2):148–52.
13. Cederholm T, Wretlind B, Hellstrom K, Andersson B, Engstrom L, Brismar K, et al. Enhanced 
generation of interleukins 1 beta and 6 may contribute to the cachexia of chronic disease. Am J 
Clin Nutr. 1997; 65(3):876–82. [PubMed: 9062543] 
14. Guma M, Tiziani S, Firestein GS. Metabolomics in rheumatic diseases: desperately seeking 
biomarkers. Nat Rev Rheumatol. 2016; 12(5):269–81. [PubMed: 26935283] 
15. Alonso A, Julià A, Vinaixa M, Domènech E, Fernández-Nebro A, Cañete JD, et al. Urine 
metabolome profiling of immune-mediated inflammatory diseases. BMC Medicine. 2016; 14(1):
133. [PubMed: 27609333] 
Falconer et al. Page 14
Arthritis Rheumatol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
16. Young SP, Kapoor SR, Viant MR, Byrne JJ, Filer A, Buckley CD, et al. The impact of 
inflammation on metabolomic profiles in patients with arthritis. Arthritis Rheum. 2013; 65(8):
2015–23. [PubMed: 23740368] 
17. Madsen RK, Lundstedt T, Gabrielsson J, Sennbro CJ, Alenius GM, Moritz T, et al. Diagnostic 
properties of metabolic perturbations in rheumatoid arthritis. Arthritis research & therapy. 2011; 
13(1):R19. [PubMed: 21303541] 
18. Hugle T, Kovacs H, Heijnen IA, Daikeler T, Baisch U, Hicks JM, et al. Synovial fluid 
metabolomics in different forms of arthritis assessed by nuclear magnetic resonance spectroscopy. 
Clinical and experimental rheumatology. 2012; 30(2):240–5. [PubMed: 22410098] 
19. Kim S, Hwang J, Xuan J, Jung YH, Cha H-S, Kim KH. Global Metabolite Profiling of Synovial 
Fluid for the Specific Diagnosis of Rheumatoid Arthritis from Other Inflammatory Arthritis. 
PLOS ONE. 2014; 9(6):e97501. [PubMed: 24887281] 
20. Cuppen BVJ, Fu J, van Wietmarschen HA, Harms AC, Koval S, Marijnissen ACA, et al. Exploring 
the Inflammatory Metabolomic Profile to Predict Response to TNF-α Inhibitors in Rheumatoid 
Arthritis. PLOS ONE. 2016; 11(9):e0163087. [PubMed: 27631111] 
21. Sweeney SR, Kavanaugh A, Lodi A, Wang B, Boyle D, Tiziani S, et al. Metabolomic profiling 
predicts outcome of rituximab therapy in rheumatoid arthritis. RMD Open. 2016; 2(2):e000289. 
[PubMed: 27651926] 
22. Tatar Z, Migne C, Petera M, Gaudin P, Lequerre T, Marotte H, et al. Variations in the metabolome 
in response to disease activity of rheumatoid arthritis. BMC Musculoskeletal Disorders. 2016; 
17(1):353. [PubMed: 27549132] 
23. Smith MD. The Normal Synovium. The Open Rheumatology Journal. 2011; 5:100–6. [PubMed: 
22279508] 
24. Misharin AV, Cuda CM, Saber R, Turner JD, Gierut AK, Haines GK 3rd, et al. Nonclassical 
Ly6C(−) monocytes drive the development of inflammatory arthritis in mice. Cell Rep. 2014; 9(2):
591–604. [PubMed: 25373902] 
25. Udalova IA, Mantovani A, Feldmann M. Macrophage heterogeneity in the context of rheumatoid 
arthritis. Nat Rev Rheumatol. 2016; 12(8):472–85. [PubMed: 27383913] 
26. Bottini N, Firestein GS. Duality of fibroblast-like synoviocytes in RA: passive responders and 
imprinted aggressors. Nat Rev Rheumatol. 2013; 9(1):24–33. [PubMed: 23147896] 
27. Croft AP, Naylor AJ, Marshall JL, Hardie DL, Zimmermann B, Turner J, et al. Rheumatoid 
synovial fibroblasts differentiate into distinct subsets in the presence of cytokines and cartilage. 
Arthritis research & therapy. 2016; 18:270. [PubMed: 27863512] 
28. Mizoguchi FSK, Chang SK, Rao DA, Nguyen H, Noss EH, Earp BE, Blazar PE, Wright J, 
Simmons BP, Hacohen N, Nigrovic PA, Raychaudhuri S, Brenner MB. Identification of Synovial 
Fibroblast Subsets That Define Pathology in Rheumatoid Arthritis [abstract]. Arthritis & 
Rheumatology. 2015; 67(supplement 10)
29. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature. 2003; 423(6937):356–61. 
[PubMed: 12748655] 
30. Bartok B, Firestein GS. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. 
Immunol Rev. 2010; 233(1):233–55. [PubMed: 20193003] 
31. Biniecka M, Fox E, Gao W, Ng CT, Veale DJ, Fearon U, et al. Hypoxia induces mitochondrial 
mutagenesis and dysfunction in inflammatory arthritis. Arthritis Rheum. 2011; 63(8):2172–82. 
[PubMed: 21484771] 
32. Gaber T, Dziurla R, Tripmacher R, Burmester GR, Buttgereit F. Hypoxia inducible factor (HIF) in 
rheumatology: low O2! See what HIF can do! Ann Rheum Dis. 2005; 64(7):971–80. [PubMed: 
15800008] 
33. Szekanecz Z, Besenyei T, Paragh G, Koch AE. Angiogenesis in rheumatoid arthritis. 
Autoimmunity. 2009; 42(7):563–73. [PubMed: 19863375] 
34. Ahn, JK., Kim, S., Hwang, J., Kim, J., Kim, KH., Cha, HS. Joint Bone Spine. 2016. GC/TOF-MS-
based metabolomic profiling in cultured fibroblast-like synoviocytes from rheumatoid arthritis. 
35. Guma M, Sanchez-Lopez E, Lodi A, Garcia-Carbonell R, Tiziani S, Karin M, et al. Choline kinase 
inhibition in rheumatoid arthritis. Ann Rheum Dis. 2015; 74(7):1399–407. [PubMed: 25274633] 
Falconer et al. Page 15
Arthritis Rheumatol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
36. Kurowska-Stolarska M, Alivernini S. Synovial tissue macrophages: friend or foe? RMD Open. 
2017; 3(2)
37. Weyand CM, Zeisbrich M, Goronzy JJ. Metabolic signatures of T-cells and macrophages in 
rheumatoid arthritis. Current Opinion in Immunology. 2017; 46:112–20. [PubMed: 28538163] 
38. Nayar S, Campos J, Steinthal N, Barone F. Tissue Digestion for Stromal Cell and Leukocyte 
Isolation. Methods in molecular biology (Clifton, NJ). 2017; 1591:225–34.
39. Ghesquiere B, Wong BW, Kuchnio A, Carmeliet P. Metabolism of stromal and immune cells in 
health and disease. Nature. 2014; 511(7508):167–76. [PubMed: 25008522] 
40. Lemons JM, Feng XJ, Bennett BD, Legesse-Miller A, Johnson EL, Raitman I, et al. Quiescent 
fibroblasts exhibit high metabolic activity. PLoS Biol. 2010; 8(10):e1000514. [PubMed: 
21049082] 
41. O’Neill LAJ, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. 
Nature. 2013; 493(7432):346–55. [PubMed: 23325217] 
42. Weichhart T, Hengstschlager M, Linke M. Regulation of innate immune cell function by mTOR. 
Nat Rev Immunol. 2015; 15(10):599–614. [PubMed: 26403194] 
43. Yuan H-X, Xiong Y, Guan K-L. Nutrient sensing, metabolism, and cell growth control. Molecular 
cell. 2013; 49(3):379–87. [PubMed: 23395268] 
44. Vincent EE, Coelho PP, Blagih J, Griss T, Viollet B, Jones RG. Differential effects of AMPK 
agonists on cell growth and metabolism. Oncogene. 2015; 34(28):3627–39. [PubMed: 25241895] 
45. Covarrubias AJ, Aksoylar HI, Horng T. Control of macrophage metabolism and activation by 
mTOR and Akt signaling. Seminars in immunology. 2015; 27(4):286–96. [PubMed: 26360589] 
46. Guma M, Wang Y, Viollet B, Liu-Bryan R. AMPK Activation by A-769662 Controls IL-6 
Expression in Inflammatory Arthritis. PLoS ONE. 2015; 10(10):e0140452. [PubMed: 26474486] 
47. Park SY, Lee SW, Lee SY, Hong KW, Bae SS, Kim K, et al. SIRT1/Adenosine Monophosphate-
Activated Protein Kinase α Signaling Enhances Macrophage Polarization to an Anti-inflammatory 
Phenotype in Rheumatoid Arthritis. Front Immunol. 2017; 8:1135. [PubMed: 28966618] 
48. Wruck CJ, Fragoulis A, Gurzynski A, Brandenburg LO, Kan YW, Chan K, et al. Role of oxidative 
stress in rheumatoid arthritis: insights from the Nrf2-knockout mice. Ann Rheum Dis. 2011; 70(5):
844–50. [PubMed: 21173018] 
49. Jornayvaz FR, Shulman GI. Regulation of mitochondrial biogenesis. Essays Biochem. 2010; 
47:69–84. [PubMed: 20533901] 
50. Osellame LD, Blacker TS, Duchen MR. Cellular and molecular mechanisms of mitochondrial 
function. Best Pract Res Clin Endocrinol Metab. 2012; 26(6):711–23. [PubMed: 23168274] 
51. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. Emerging role of 
damage-associated molecular patterns derived from mitochondria in inflammation. Trends 
Immunol. 2011; 32(4):157–64. [PubMed: 21334975] 
52. Wai T, Langer T. Mitochondrial Dynamics and Metabolic Regulation. Trends in Endocrinology & 
Metabolism. 27(2):105–17.
53. Seo AY, Joseph AM, Dutta D, Hwang JC, Aris JP, Leeuwenburgh C. New insights into the role of 
mitochondria in aging: mitochondrial dynamics and more. Journal of cell science. 2010; 123(Pt 
15):2533–42. [PubMed: 20940129] 
54. Corcoran SE, O’Neill LA. HIF1alpha and metabolic reprogramming in inflammation. J Clin Invest. 
2016; 126(10):3699–707. [PubMed: 27571407] 
55. Mills E, O’Neill LA. Succinate: a metabolic signal in inflammation. Trends Cell Biol. 2014; 24(5):
313–20. [PubMed: 24361092] 
56. Lampropoulou V, Sergushichev A, Bambouskova M, Nair S, Vincent EE, Loginicheva E, et al. 
Itaconate Links Inhibition of Succinate Dehydrogenase with Macrophage Metabolic Remodeling 
and Regulation of Inflammation. Cell Metab. 2016; 24(1):158–66. [PubMed: 27374498] 
57. Hollander AP, Corke KP, Freemont AJ, Lewis CE. Expression of hypoxia-inducible factor 1alpha 
by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the 
inflamed joint. Arthritis Rheum. 2001; 44(7):1540–4. [PubMed: 11465705] 
Falconer et al. Page 16
Arthritis Rheumatol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
58. Kim EK, Kwon JE, Lee SY, Lee EJ, Kim DS, Moon SJ, et al. IL-17-mediated mitochondrial 
dysfunction impairs apoptosis in rheumatoid arthritis synovial fibroblasts through activation of 
autophagy. Cell Death Dis. 2017; 8(1):e2565.
59. Biniecka M, Canavan M, McGarry T, Gao W, McCormick J, Cregan S, et al. Dysregulated 
bioenergetics: a key regulator of joint inflammation. Ann Rheum Dis. 2016
60. Garcia-Carbonell R, Divakaruni AS, Lodi A, Vicente-Suarez I, Saha A, Cheroutre H, et al. Critical 
role of fibroblast-like synoviocytes glycolytic metabolism in rheumatoid arthritis. Arthritis 
Rheumatol. 2016
61. Fearon U, Canavan M, Biniecka M, Veale DJ. Hypoxia, mitochondrial dysfunction and synovial 
invasiveness in rheumatoid arthritis. Nat Rev Rheumatol. 2016
62. Ng CT, Biniecka M, Kennedy A, McCormick J, FitzGerald O, Bresnihan B, et al. Synovial tissue 
hypoxia and inflammation in vivo. Annals of the Rheumatic Diseases. 2010
63. Da Sylva TR, Connor A, Mburu Y, Keystone E, Wu GE. Somatic mutations in the mitochondria of 
rheumatoid arthritis synoviocytes. Arthritis research & therapy. 2005; 7(4):R844–51. [PubMed: 
15987486] 
64. Harty LC, Biniecka M, O’Sullivan J, Fox E, Mulhall K, Veale DJ, et al. Mitochondrial mutagenesis 
correlates with the local inflammatory environment in arthritis. Ann Rheum Dis. 2012; 71(4):582–
8. [PubMed: 22121133] 
65. Pope RM. Apoptosis as a therapeutic tool in rheumatoid arthritis. Nature Reviews Immunology. 
2002; 2:527.
66. Mayers JR, Vander Heiden MG. Famine versus feast: understanding the metabolism of tumors in 
vivo. Trends in biochemical sciences. 2015; 40(3):130–40. [PubMed: 25639751] 
67. Bell C, English L, Boulais J, Chemali M, Caron-Lizotte O, Desjardins M, et al. Quantitative 
Proteomics Reveals the Induction of Mitophagy in Tumor Necrosis Factor-α-activated (TNFα) 
Macrophages. Molecular & Cellular Proteomics: MCP. 2013; 12(9):2394–407. [PubMed: 
23674617] 
68. Xu K, Xu P, Yao JF, Zhang YG, Hou WK, Lu SM. Reduced apoptosis correlates with enhanced 
autophagy in synovial tissues of rheumatoid arthritis. Inflammation research: official journal of the 
European Histamine Research Society [et al]. 2013; 62(2):229–37.
69. Zhang J, Song X, Cao W, Lu J, Wang X, Wang G, et al. Autophagy and mitochondrial dysfunction 
in adjuvant-arthritis rats treatment with resveratrol. Sci Rep. 2016; 6:32928. [PubMed: 27611176] 
70. Shin YJ, Han SH, Kim DS, Lee GH, Yoo WH, Kang YM, et al. Autophagy induction and CHOP 
under-expression promotes survival of fibroblasts from rheumatoid arthritis patients under 
endoplasmic reticulum stress. Arthritis Res Ther. 2010; 12(1):R19. [PubMed: 20122151] 
71. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic 
requirements of cell proliferation. Science. 2009; 324(5930):1029–33. [PubMed: 19460998] 
72. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004; 
4(11):891–9. [PubMed: 15516961] 
73. Kubota K, Ito K, Morooka M, Mitsumoto T, Kurihara K, Yamashita H, et al. Whole-body FDG-
PET/CT on rheumatoid arthritis of large joints. Annals of nuclear medicine. 2009; 23(9):783–91. 
[PubMed: 19834653] 
74. Weyand CM, Goronzy JJ. Immunometabolism in early and late stages of rheumatoid arthritis. Nat 
Rev Rheumatol. 2017; 13(5):291–301. [PubMed: 28360422] 
75. Volchenkov R, Dung Cao M, Elgstoen KB, Goll GL, Eikvar K, Bjorneboe O, et al. Metabolic 
profiling of synovial tissue shows altered glucose and choline metabolism in rheumatoid arthritis 
samples. Scand J Rheumatol. 2016:1–2.
76. Yang Z, Fujii H, Mohan SV, Goronzy JJ, Weyand CM. Phosphofructokinase deficiency impairs 
ATP generation, autophagy, and redox balance in rheumatoid arthritis T cells. J Exp Med. 2013; 
210(10):2119–34. [PubMed: 24043759] 
77. Ahn JK, Kim S, Hwang J, Kim J, Kim KH, Cha HS. GC/TOF-MS-based metabolomic profiling in 
cultured fibroblast-like synoviocytes from rheumatoid arthritis. Joint Bone Spine. 2016; 83(6):
707–13. [PubMed: 27133762] 
Falconer et al. Page 17
Arthritis Rheumatol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
78. Li Y, Zheng JY, Liu JQ, Yang J, Liu Y, Wang C, et al. Succinate/NLRP3 Inflammasome Induces 
Synovial Fibroblast Activation: Therapeutical Effects of Clematichinenoside AR on Arthritis. 
Front Immunol. 2016; 7:532. [PubMed: 28003810] 
79. Chang CH, Curtis JD, Maggi LB Jr, Faubert B, Villarino AV, O’Sullivan D, et al. 
Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell. 2013; 153(6):
1239–51. [PubMed: 23746840] 
80. Yu X, Li S. Non-metabolic functions of glycolytic enzymes in tumorigenesis. Oncogene. 2016
81. Moon JS, Hisata S, Park MA, DeNicola GM, Ryter SW, Nakahira K, et al. mTORC1-Induced 
HK1-Dependent Glycolysis Regulates NLRP3 Inflammasome Activation. Cell reports. 2015; 
12(1):102–15. [PubMed: 26119735] 
82. Nomura M, Liu J, Rovira II, Gonzalez-Hurtado E, Lee J, Wolfgang MJ, et al. Fatty acid oxidation 
in macrophage polarization. Nature immunology. 2016; 17(3):216–7. [PubMed: 26882249] 
83. Roivainen A, Parkkola R, Yli-Kerttula T, Lehikoinen P, Viljanen T, Mottonen T, et al. Use of 
positron emission tomography with methyl-11C-choline and 2-18F-fluoro-2-deoxy-D-glucose in 
comparison with magnetic resonance imaging for the assessment of inflammatory proliferation of 
synovium. Arthritis Rheum. 2003; 48(11):3077–84. [PubMed: 14613269] 
84. Seki M, Kawai Y, Ishii C, Yamanaka T, Odawara M, Inazu M. Functional analysis of choline 
transporters in rheumatoid arthritis synovial fibroblasts. Modern rheumatology. 2017:1–9.
85. Lim HK, Choi YA, Park W, Lee T, Ryu SH, Kim SY, et al. Phosphatidic acid regulates systemic 
inflammatory responses by modulating the Akt-mammalian target of rapamycin-p70 S6 kinase 1 
pathway. J Biol Chem. 2003; 278(46):45117–27. [PubMed: 12960176] 
86. Friday SC, Fox DA. Phospholipase D enzymes facilitate IL-17- and TNFalpha-induced expression 
of proinflammatory genes in rheumatoid arthritis synovial fibroblasts (RASF). Immunol Lett. 
2016; 174:9–18. [PubMed: 27058440] 
87. Fuchs B, Schiller J, Wagner U, Hantzschel H, Arnold K. The phosphatidylcholine/
lysophosphatidylcholine ratio in human plasma is an indicator of the severity of rheumatoid 
arthritis: investigations by 31P NMR and MALDI-TOF MS. Clin Biochem. 2005; 38(10):925–33. 
[PubMed: 16043165] 
88. Bourgoin SG, Zhao C. Autotaxin and lysophospholipids in rheumatoid arthritis. Curr Opin Investig 
Drugs. 2010; 11(5):515–26.
89. Miyabe Y, Miyabe C, Iwai Y, Yokoyama W, Sekine C, Sugimoto K, et al. Activation of fibroblast-
like synoviocytes derived from rheumatoid arthritis via lysophosphatidic acid-lysophosphatidic 
acid receptor 1 cascade. Arthritis Res Ther. 2014; 16(5):461. [PubMed: 25273676] 
90. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, et al. 
Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled 
arthritis. J Exp Med. 2012; 209(5):925–33. [PubMed: 22493518] 
91. Halestrap AP. Monocarboxylic acid transport. Compr Physiol. 2013; 3(4):1611–43. [PubMed: 
24265240] 
92. Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et 
al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor 
stroma. Cell Cycle. 2009; 8(23):3984–4001. [PubMed: 19923890] 
93. Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, et al. Warburg meets autophagy: 
cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, 
mitophagy, and aerobic glycolysis. Antioxidants & redox signaling. 2012; 16(11):1264–84. 
[PubMed: 21883043] 
94. Vegran F, Boidot R, Michiels C, Sonveaux P, Feron O. Lactate influx through the endothelial cell 
monocarboxylate transporter MCT1 supports an NF-kappaB/IL-8 pathway that drives tumor 
angiogenesis. Cancer research. 2011; 71(7):2550–60. [PubMed: 21300765] 
95. Fujii W, Kawahito Y, Nagahara H, Kukida Y, Seno T, Yamamoto A, et al. Monocarboxylate 
transporter 4, associated with the acidification of synovial fluid, is a novel therapeutic target for 
inflammatory arthritis. Arthritis Rheumatol. 2015; 67(11):2888–96. [PubMed: 26213210] 
96. Sanita P, Capulli M, Teti A, Galatioto GP, Vicentini C, Chiarugi P, et al. Tumor-stroma metabolic 
relationship based on lactate shuttle can sustain prostate cancer progression. BMC cancer. 2014; 
14:154. [PubMed: 24597899] 
Falconer et al. Page 18
Arthritis Rheumatol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
97. Metallo, CM. Metabolic analysis using stable isotopes. Metallo, CM., editor. United States: 
Waltham, MA: Elsevier Academic Press; 2015. 
98. Zamboni N. 13 C metabolic flux analysis in complex systems. Current opinion in biotechnology. 
2011; 22(1):103–8. [PubMed: 20833526] 
99. Birkemeyer C, Luedemann A, Wagner C, Erban A, Kopka J. Metabolome analysis: the potential of 
in vivo labeling with stable isotopes for metabolite profiling. Trends in biotechnology. 2005; 23(1):
28–33. [PubMed: 15629855] 
100. Rodrigues TB, Serrao EM, Kennedy BW, Hu D-E, Kettunen MI, Brindle KM. Magnetic 
resonance imaging of tumor glycolysis using hyperpolarized 13C-labeled glucose. Nature 
medicine. 2014; 20(1):93–7.
101. Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, et al. Acetyl-CoA Synthetase 2 
Promotes Acetate Utilization and Maintains Cancer Cell Growth under Metabolic Stress. Cancer 
cell. 2015; 27(1):57–71. [PubMed: 25584894] 
102. Choi J, Grossbach MT, Antoniewicz MR. Measuring complete isotopomer distribution of 
aspartate using gas chromatography/tandem mass spectrometry. Analytical chemistry. 2012; 
84(10):4628–32. [PubMed: 22510303] 
103. Ahn JK, Kim S, Hwang J, Kim J, Lee YS, Koh EM, et al. Metabolomic Elucidation of the Effects 
of Curcumin on Fibroblast-Like Synoviocytes in Rheumatoid Arthritis. PLoS One. 2015; 
10(12):e0145539. [PubMed: 26716989] 
104. Rocha B, Ruiz-Romero C, Blanco FJ. Mass spectrometry imaging: a novel technology in 
rheumatology. Nat Rev Rheumatol. 2017; 13(1):52–63. [PubMed: 27881864] 
105. Galluzzi L, Kepp O, Vander Heiden MG, Kroemer G. Metabolic targets for cancer therapy. Nat 
Rev Drug Discov. 2013; 12(11):829–46. [PubMed: 24113830] 
106. Lories RJ, Derese I, De Bari C, Luyten FP. In vitro growth rate of fibroblast-like synovial cells is 
reduced by methotrexate treatment. Ann Rheum Dis. 2003; 62(6):568–71. [PubMed: 12759297] 
107. Vergne-Salle P, Leger DY, Bertin P, Treves R, Beneytout JL, Liagre B. Effects of the active 
metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in 
human rheumatoid arthritis synoviocytes. Cytokine. 2005; 31(5):335–48. [PubMed: 16099671] 
108. Timmerman LA, Holton T, Yuneva M, Louie RJ, Padro M, Daemen A, et al. Glutamine sensitivity 
analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. 
Cancer Cell. 2013; 24(4):450–65. [PubMed: 24094812] 
109. Buck MD, O’Sullivan D, Klein Geltink RI, Curtis JD, Chang CH, Sanin DE, et al. Mitochondrial 
Dynamics Controls T Cell Fate through Metabolic Programming. Cell. 2016; 166(1):63–76. 
[PubMed: 27293185] 
110. Son HJ, Lee J. Metformin attenuates experimental autoimmune arthritis through reciprocal 
regulation of Th17/Treg balance and osteoclastogenesis. 2014; 2014:973986.
111. Massacesi C, Di Tomaso E, Urban P, Germa C, Quadt C, Trandafir L, et al. PI3K inhibitors as 
new cancer therapeutics: implications for clinical trial design. OncoTargets and therapy. 2016; 
9:203–10. [PubMed: 26793003] 
112. Schoors S, De Bock K, Cantelmo AR, Georgiadou M, Ghesquiere B, Cauwenberghs S, et al. 
Partial and transient reduction of glycolysis by PFKFB3 blockade reduces pathological 
angiogenesis. Cell metabolism. 2014; 19(1):37–48. [PubMed: 24332967] 
113. Raza K, Filer A. The therapeutic window of opportunity in rheumatoid arthritis: does it ever 
close? Ann Rheum Dis. 2015; 74(5):793–4. [PubMed: 25757869] 
Falconer et al. Page 19
Arthritis Rheumatol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. Similarities between the rheumatoid arthritis synovium and the solid tumor 
microenvironment
In both tissues, fibroblasts and macrophages (MØ) reside in close proximity and within an 
oxygen and nutrient deprived, cytokine rich environment. Here they sustain mitochondrial 
damage and take on a chronically activated phenotype supported by increased glycolytic 
metabolism. In RA, the fibroblasts themselves are proliferative, invasive and migratory 
while in cancer fibroblasts support proliferation, invasion and metastasis of tumor cells. 
Adaptive immune cell-fibroblast interactions differ in tumor and RA microenvironments. 
Activated T (green) and B (blue) cells are present in the synovium in RA but are suppressed 
in the tumor microenvironment. Little is known about fibroblast or macrophage metabolism 
in early RA and the metabolic changes which take place during the transition from health to 
disease. (ROS, reactive oxygen species).
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Figure 2. Major pathways important in synoviocyte metabolism
FLS and monocyte derived macrophages are heavily reliant upon glucose metabolism and 
regulate glucose transporter member 1 (Glut1) in response to inflammatory and stress 
stimuli. This fuels adenosine triphosphate (ATP) production in conditions of high energetic 
demand. Glucose is utilized in the pentose phosphate pathway to synthesize building blocks 
for nucleic acids, and to generate NADPH to control redox status and support lipid 
synthesis. Alternatively glucose is metabolized via glycolysis to pyruvate which is either 
transported into the mitochondria to contribute to tricarboxylic acid (TCA) cycle flux or is 
converted to lactate in the cytoplasm and removed from the cell via monocarboxylate 
transporter 4 (MCT4). TCA cycle flux contributes to ATP production via oxidative and 
substrate level phosphorylation. When matrix citrate levels rise, citrate is transported to the 
cytoplasm and yields acetyl-CoA, the starting material for synthesis of fatty acids, 
cholesterol and lipids. Some such lipids are exported from the cell as bioactive metabolites 
such as sphingosine 1 phosphate (S1P), free fatty acids (FFA), phospholipids and 
eicosanoids. Acetyl-CoA as well as succinate generated from the TCA cycle can be utilized 
in production chromatin modifying enzymes (CME) and cofactors. Choline is taken up via 
choline transporter-like (CTL) 1/2 is an important substrate in FLS biology. Choline can be 
converted to betaine which is used in production CME and cofactors or converted to glycine 
for use in protein synthesis. Alternatively, choline is phosphorylated to phosphocholine and 
utilized in membrane phospholipid and bioactive lipid synthesis. A number of signalling 
molecules have been identified which control the described metabolic pathways but have 
sparsely been explored in FLS. AKT, protein kinase B; AMPK, 5′ adenosine 
monophosphate-activated protein kinase; G6P, glucose-6-phosphate; HIF-1α, hypoxia-
inducible factor 1α; Myc, Myc proto-oncogene protein; p53, cellular tumor antigen p53; 
PI3K, phosphatidylinositol 4,5-bisphosphate 3-kinase; R5P, ribose-5-phosphate; S1P, 
sphingosine-1-phosphate; SREBP, sterol regulatory element-binding protein; mTOR, 
mechanistic target of rapamycin; PPARγ, peroxisome proliferator-activated receptor 
gamma; NF-κB, nuclear factor κB pathway; uPFK, 2phosphofructokinase 2.
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Figure 3. Mitochondrial dynamics; the cycle of fusion and fission
Mitochondrial morphology changes dynamically in response to stress and changing 
energetic demand. This is under the control of signalling molecules including sirtuin 1 
(SIRT1), signal transducer and activator of transcription 6 (STAT6), nuclear respiratory 
factors 1 and 2 (NRF1/2) and peroxisome proliferator-activated receptor gamma coactivators 
1α and β (PGC-1α/β). Mitochondria fuse to make tubular networks under the control of 
mitofusins (MFN) 1 and 2 and optic atrophy (OPA1), a mechanism which is thought to 
increase ATP production by oxidative phosphorylation, protect mitochondrial DNA from 
damage in the presence of elevated reactive oxygen species (ROS) and leads to 
mitochondrial biogenesis and increased mitochondrial mass. Mitochondrial fission occurs 
under the control of dynamin related protein 1 (DRP1) and mitochondrial fission 1 (FIS1) 
and produces increased numbers of punctate mitochondria. Fission usually corresponds with 
reduced oxidative phosphorylation and increased aerobic glycolysis and can predispose to 
mitochondrial-selective autophagy (mitophagy) to regulate mitochondrial mass or remove 
damaged organelles. The box shows a number of mitochondrial observations made in FLS 
cultured from RA patients both in a resting state and after stimulation with proinflammatory 
cytokines, alluding to possible but as yet uninvestigated changes in mitochondrial dynamics.
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Figure 4. The ‘reverse Warburg’ effect in cancer and rheumatoid arthritis?
In epithelial tumours, the reactive oxygen species (ROS) produced by metabolically active 
cancer cells causes mitochondria-selective autophagy (mitophagy) and activate hypoxia 
inducible factor 1α (HIF1α) in local cancer-associated fibroblasts (CAF). As a result the 
CAF upregulate aerobic glycolysis, producing copious lactate which is expelled from the 
cell via monocarboxylate transporter 4 (MCT4) and taken up by the cancer cell via MCT1. 
Lactate, pyruvate and other metabolic intermediates such as amino acids and ketone bodies 
can feed the mitochondrial TCA cycle in cancer cells or indeed local endothelium to 
increase ATP and biomolecule synthesis and drive pathogenic proliferation, invasion and 
metastasis. MCT 1 and 4 can be blocked in vitro using the small molecule inhibitor α-
cyano-4-hydroxycinnamic acid (4CIN) and in vivo using AZD3965, which is in early phase 
clinical trials for treatment of small cell lung cancer. In RA it is known that mitochondrial 
damage, HIF1α activation and upregulation of MCT4 can be induced in late stage disease 
FLS by the pathogenic microenvironment but the metabolic relationships between these cells 
and other cells within the joint have yet to be elucidated.
Falconer et al. Page 23
Arthritis Rheumatol. Author manuscript; available in PMC 2019 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Falconer et al. Page 24
Table 1
Term Definition in the context of this review
Aerobic glycolysis The metabolic pathway which utilizes glucose to generate ATP in the presence of oxygen. End products of 
this process are pyruvate which can be imported into mitochondria for use in the TCA cycle or lactate which 
is expelled from the cell as waste.
Anabolism The enzymatic synthesis of molecules from smaller components.
Anaplerosis The replenishment of metabolic intermediates into the TCA cycle as substrates for biosynthesis and the 
generation of ATP.
Bioenergetics The study of energy production by cells. Often associated with use of the Seahorse analyzer to assess 
glycolysis and oxidative phosphorylation rates in real time.
Catabolism The enzymatic degradation of molecules into smaller products.
Cataplerosis The removal of TCA cycle intermediates for use in biosynthesis or to prevent build up within mitochondria.
Electron transport chain A set of complexes of the inner mitochondrial membrane that shuttle electrons from NADH and FADH2 to 
oxygen. The redox reactions of the chain produce an electrochemical gradient of protons across the 
membrane which drives synthesis of ATP by oxidative phosphorylation.
Hypoxia Oxygen deficiency in tissues, such that oxygen tension is below that of healthy physiological conditions. 
Normal oxygen levels differ between tissues and therefore the level at which a tissue is considered to be 
hypoxic is variable. The RA joint has an oxygen tension of 8% in health and <3% in RA.
Imaging mass spectrometry A mass spectrometry based technique which allows the spatial distribution of the metabolome to be 
visualized in a tissue section. This offers insights into where pathogenic metabolic changes are taking place in 
tissues and is yet to be applied to the synovium.
Immunometabolism The research field which investigates metabolism in the context of immunity and inflammation. As stromal 
cells are crucial to both induction and resolution of these processes, we consider the study of their metabolic 
processes to be embedded in this field.
Metabolic coupling The transfer of metabolites between cells in a manner which benefits the biosynthetic and bioenergetic 
requirements of the recipient cell.
Metabolic flux analysis Also known as ‘stable isotope metabolic tracer analysis’, this is a 13C isotope tracing methodology involving 
incubation of cells with a stable isotope, quantitation of metabolite labeling using mass spectrometry or NMR 
spectroscopy, and computational fitting of the data to a model allowing estimates of pathway-specific flux.
Metabolic memory Imprinting of a metabolic phenotype on a cell by cues within its microenvironment, such that the phenotype 
is maintained after the cues are removed or the cells is removed from the tissue.
Metabolome All substrates, intermediates and products of metabolism associated with a given system or compartment. 
These may be intracellular or extracellular.
Metabolomics Used synonymously with the term ‘metabolic profiling’, this is the identification and measurement of all or a 
targeted set of metabolites within a body fluid, cell population or tissue conducted by NMR spectroscopy or 
mass spectrometry.
Mitochondrial biogenesis The generation of greater mitochondrial mass to increase the capacity for mitochondrial function and ATP 
production within a cell; this process is important to health but is uninvestigated in RA.
Mitochondrial dynamics The balance and transition between mitochondrial fusion and fission, movement and degradation; processes 
which are important to health but in uninvestigated in RA.
Mitochondrial fission The division of mitochondrial networks into individual, punctate organelles, principally controlled by outer 
membrane proteins DRP1 and FIS1.
Mitochondrial fusion The formation of tubular mitochondrial networks through MFN1, MFN2 and OPA1 mediated joining of 
individual organelle membranes. This process is associated with increased ATP production and protection of 
mitochondrial DNA from reactive oxygen species.
Mitophagy ‘Mitochondrial-selective autophagy’. The selective degradation of defective mitochondria without the release 
of inflammatory mitochondria- associated DAMPS.
Oxidative phosphorylation Generation of ATP by the mitochondrial ATP synthase and driven by the electrochemical gradient of protons 
generated by the electron transport chain.
Pentose phosphate pathway The pathway which oxidizes glucose to generate NADPH for the maintenance of the cellular redox balance 
and 5 carbon sugars utilized in anabolic processes such as nucleic acid synthesis.
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Term Definition in the context of this review
Positron emission tomography Use of a radioactive tracer isotope incorporated into a metabolic substrate to visualize metabolizing cells in a 
whole organism. Commonly, labelled glucose is used to identify tumors but is also useful in highlighting sites 
of inflammation such as the RA joint.
Reverse Warburg effect – The production of high energy metabolic intermediates by one cell to anaplerotically feed ATP production by 
a neighboring cell. Currently characterized only in epithelial tumors where cancer-associated fibroblast feed 
lactate and other metabolites to tumor cells through channels such as the monocarboxylate transporters.
TCA cycle The tricarboxylic acid cycle is a series of chemical reactions which take place in the mitochondrial matrix 
generating ATP by substrate level phosphorylation and NADH and FADH2 by oxidation of fuel molecules. 
The NADH and FADH2 are further oxidized by the electron transport chain.
Warburg effect Pathological increase in glycolysis associated with reduced oxidative phosphorylation despite the presence of 
oxygen. This describes a cellular bioenergetic phenotype classically associated with tumor cells but now also 
associated with activated immune cells.
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